Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellSpring To Make U.S. Debut With Acquisition Of McNeil’s Micatin, Emetrol

This article was originally published in The Tan Sheet

Executive Summary

WellSpring Pharmaceutical Corporation will enter the U.S. OTC market with its purchase of the U.S. rights to several smaller brands from McNeil Consumer Healthcare

You may also be interested in...



Wellspring

Neptune, N.J.-based firm completes acquisition of Shire Pharmaceutical Group's Canadian OTC product line, company announces Sept. 4. OTC line includes over 12 products ranging from laxatives to an anti-fungal cream to potassium supplements and will be produced in a recently acquired (also from Shire) Oakville, Ontario plant. Line will serve as springboard for expansion into U.S., Wellspring says. Company will "relaunch these products...with a renewed marketing push" and plans to reintroduce several discontinued Shire products. Later this year, Wellspring also will add "at least one new OTC brand for treatment of several different and common gastrointestinal disorders"

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Topics

UsernamePublicRestriction

Register

PS102086

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel